Clinical Trials
56
Active:10
Completed:30
Trial Phases
5 Phases
Phase 1:5
Phase 2:1
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (38.5%)Phase 3
3 (23.1%)Phase 4
3 (23.1%)Not Applicable
1 (7.7%)Phase 2
1 (7.7%)Registry Platform Myelofibrosis and Anemia
Not yet recruiting
- Conditions
- Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisMyelofibrosisSecondary MyelofibrosisAnemiaMyelofibrosis; AnemiaPost-polycythemia Vera Myelofibrosis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 200
- Registration Number
- NCT06976918
- Locations
- 🇩🇪
Multiple sites all over Germany, Multiple Locations, Germany
Fruquintinib in Patients With Metastatic Colorectal Cancer
Recruiting
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 150
- Registration Number
- NCT06787105
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Hannover, Niedersachsen, Germany
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Recruiting
- Conditions
- Polycythemia Vera
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 200
- Registration Number
- NCT06743035
- Locations
- 🇩🇪
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde, Hannover, Niedersachsen, Germany
Ripretinib (QINLOCK®) According to Current SmPC
Recruiting
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06619275
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
Recruiting
- Conditions
- Cholangiocarcinoma
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06607302
- Locations
- 🇩🇪
Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany
🇩🇪Onkologisches Versorgungszentrum Berlin MVZ, Berlin, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found